Enterprise Value
-2.859M
Cash
10.9M
Avg Qtr Burn
-3.757M
Short % of Float
2.49%
Insider Ownership
0.50%
Institutional Own.
5.30%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
186RNL™ (BMEDA-Chelated Rhenium NanoLiposome) Details Glioblastoma, Cancer | Phase 2 Update | |
186RNL™ (BMEDA-Chelated Rhenium NanoLiposome) Details Cancer, Breast cancer | Phase 1/2 Data readout |